60 Degrees Pharmaceuticals enrolls first patient in tafenoquine babesiosis trial

60 DEGREES PHARMACEUTICALS, INC.

First patient enrolled in randomized, double-blind, placebo-controlled trial at Tufts Medical Center.
Study is first and only clinical trial evaluating tafenoquine in human babesiosis patients.
Endpoints: time to sustained clinical resolution and molecular cure via FDA-approved nucleic acid test.
Study targets at least 24 and up to 33 patients; interim analysis planned; recruitment during 2024 tick season.
Tafenoquine (ARAKODA) already FDA-approved for malaria prophylaxis; orphan drug designation for babesiosis.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.